These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 23237982)

  • 1. Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg.
    Borand L; Laureillard D; Madec Y; Chou M; Pheng P; Marcy O; Sok T; Goldfeld AE; Taburet AM; Blanc FX;
    Antivir Ther; 2013; 18(3):419-23. PubMed ID: 23237982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial).
    Borand L; Madec Y; Laureillard D; Chou M; Marcy O; Pheng P; Prak N; Kim C; Lak KK; Hak C; Dim B; Nerrienet E; Fontanet A; Sok T; Goldfeld AE; Blanc FX; Taburet AM
    PLoS One; 2014; 9(3):e90350. PubMed ID: 24608960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
    Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
    JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.
    Ren Y; Nuttall JJ; Eley BS; Meyers TM; Smith PJ; Maartens G; McIlleron HM
    J Acquir Immune Defic Syndr; 2009 Apr; 50(5):439-43. PubMed ID: 19223781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.
    von Braun A; Castelnuovo B; Ledergerber B; Cusato J; Buzibye A; Kambugu A; Fehr J; Calcagno A; Lamorde M; Sekaggya-Wiltshire C
    J Antimicrob Chemother; 2019 Jan; 74(1):135-138. PubMed ID: 30239753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efavirenz Plasma Concentrations and HIV Viral Load in HIV/AIDS-tuberculosis Infection Patients Treated with Rifampicin.
    Mariana N; Purwantyastuti ; Instiaty ; Rusli A
    Acta Med Indones; 2016 Jan; 48(1):10-6. PubMed ID: 27241539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.
    Bhatt NB; Baudin E; Meggi B; da Silva C; Barrail-Tran A; Furlan V; Grinsztejn B; Bonnet M; Taburet AM;
    J Antimicrob Chemother; 2015 Jan; 70(1):225-32. PubMed ID: 25239466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Mankatitham W; Lueangniyomkul A; Thongyen S; Eampokarap B; Uttayamakul S; Suwanvattana P; Kaewsaard S; Ruxrungtham K;
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4545-8. PubMed ID: 19667281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.
    Manosuthi W; Kiertiburanakul S; Sungkanuparph S; Ruxrungtham K; Vibhagool A; Rattanasiri S; Thakkinstian A
    AIDS; 2006 Jan; 20(1):131-2. PubMed ID: 16327334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.
    Cohen K; Grant A; Dandara C; McIlleron H; Pemba L; Fielding K; Charalombous S; Churchyard G; Smith P; Maartens G
    Antivir Ther; 2009; 14(5):687-95. PubMed ID: 19704172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
    Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin.
    Manosuthi W; Sungkanuparph S; Thakkinstian A; Vibhagool A; Kiertiburanakul S; Rattanasiri S; Prasithsirikul W; Sankote J; Mahanontharit A; Ruxrungtham K
    AIDS; 2005 Sep; 19(14):1481-6. PubMed ID: 16135901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.
    Dooley KE; Denti P; Martinson N; Cohn S; Mashabela F; Hoffmann J; Haas DW; Hull J; Msandiwa R; Castel S; Wiesner L; Chaisson RE; McIlleron H;
    J Infect Dis; 2015 Jan; 211(2):197-205. PubMed ID: 25081933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
    Luetkemeyer AF; Rosenkranz SL; Lu D; Marzan F; Ive P; Hogg E; Swindells S; Benson CA; Grinsztejn B; Sanne IM; Havlir DV; Aweeka F;
    Clin Infect Dis; 2013 Aug; 57(4):586-93. PubMed ID: 23592830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a pro-active strategy for managing tuberculosis-HIV co-infection in a UK tertiary care setting.
    Wake RM; Poulikakos P; Groth J; Harrison TS; Macallan DC
    Int J STD AIDS; 2013 Apr; 24(4):263-8. PubMed ID: 23635810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis.
    von Braun A; Sekaggya-Wiltshire C; Scherrer AU; Magambo B; Kambugu A; Fehr J; Castelnuovo B
    AIDS Res Ther; 2017 Jan; 14(1):1. PubMed ID: 28086929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
    McIlleron HM; Schomaker M; Ren Y; Sinxadi P; Nuttall JJ; Gous H; Moultrie H; Eley B; Merry C; Smith P; Haas DW; Maartens G
    AIDS; 2013 Jul; 27(12):1933-40. PubMed ID: 24180002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.
    Alghamdi WA; Antwi S; Enimil A; Yang H; Dompreh A; Wiesner L; Langaee T; Peloquin CA; Kwara A
    J Antimicrob Chemother; 2019 Sep; 74(9):2698-2706. PubMed ID: 31243456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
    Orrell C; Cohen K; Conradie F; Zeinecker J; Ive P; Sanne I; Wood R
    Antivir Ther; 2011; 16(4):527-34. PubMed ID: 21685540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.
    Bednasz CJ; Venuto CS; Ma Q; Daar ES; Sax PE; Fischl MA; Collier AC; Smith KY; Tierney C; Yang Y; Wilding GE; Morse GD
    Ther Drug Monit; 2017 Dec; 39(6):596-603. PubMed ID: 29135907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.